Hypolipidemic drug or drug preparation

A technology of pharmaceutical preparations and drugs, applied in the field of lipid-lowering drugs or pharmaceutical preparations, to meet the needs of taking medicine, excellent effect, and reduce liver fat

Inactive Publication Date: 2018-02-02
甄随民
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] There is no report on the effect of oleandrin on lipid-lowering

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Hypolipidemic drug or drug preparation
  • Hypolipidemic drug or drug preparation
  • Hypolipidemic drug or drug preparation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Example 1: The lipid-lowering effect of oleandrin

[0022] 1. Experimental animals and methods

[0023] C57BL mice, SPF grade, male, body weight (18±2) g, were randomly divided into two groups, the first group of 10 was the normal control group, given normal feed, and the remaining mice (30) were used to create hyperlipidemia The model was given a Western-style diet (20% lard, 1.25% cholesterol, 0.5% sodium cholate, and vitamins adjusted to the basic feed level) were given free access to food and water. 30 mice given Western-style diet were randomly divided into 3 groups, model group (10 mice), oleandrin group (10 mice), positive control group (lovastatin group, 10 mice), and administered by intragastric administration for 6 weeks . During the administration period, except for the normal control group which was fed with standard feed, the rest of the groups continued to be given high-fat diet until the end of the experiment. The oleandrin group was given oral gavage ...

Embodiment 2

[0038] Embodiment 2: formulation example

[0039] 1. Oleandrin Tablets

[0040] Oleandrin 10mg, starch 88g, magnesium stearate 3g.

[0041] Preparation process: Take oleandrin, mix with starch and magnesium stearate evenly, make granules, dry, and compress into tablets to obtain the product.

[0042] 2. Oleandrin Capsules

[0043] Oleandrin 10mg, starch 88g, magnesium stearate 3g.

[0044] Preparation process: Take oleandrin, mix with starch and magnesium stearate evenly, make granules, dry, pack into capsules, and obtain.

[0045] 3. Oleandrin Injection

[0046] Oleandrin 47mg, sodium chloride for injection 7mg.

[0047] Preparation process: Dissolve oleandrin with 1.9mL water for injection, add sodium chloride for injection to make it isotonic, adjust the pH value to 7-7.1, filter, refrigerate for 24 hours, add water for injection to the specified amount, filter , potting, sterilization, that is.

[0048] 4. Oleandrin and lovastatin compound tablet

[0049] Oleandrin...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a lipid-lowering medicine or medicine preparation, the active ingredient of which is oleandrin, which is made into various dosage forms by using a carrier or excipient commonly used in medicine. The present invention proves that oleandrin has a lipid-lowering effect, including reducing blood lipid and liver fat, and the effect is better after being used in combination with lovastatin, which has a synergistic effect and can be used to treat hyperlipidemia and non-alcoholic fat liver. The present invention can also prepare multiple dosage forms to meet the medication needs of different patients.

Description

technical field [0001] The invention relates to the technical field of medicines, in particular to a lipid-lowering medicine or medicine preparation. Background technique [0002] The main blood lipid components in plasma include cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-c) and high-density lipoprotein cholesterol (HDL-c). Among them, low-density lipoprotein is the chief culprit of vascular obstruction, coronary heart disease and stroke, so it is called "bad cholesterol". HDL transports LDL from the blood back to the liver, lowering the level of LDL in the blood and preventing it from depositing on the walls of blood vessels. HDL can also carry 1 / 4-3 / 4 of the cholesterol in the blood. In addition, HDL may also move excess cholesterol away from atherosclerotic plaque, so it is called "good cholesterol." [0003] Hyperlipidemia refers to a series of diseases that are directly harmful to human health caused by excessive blood lipid levels....

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/7048A61P3/06A61P1/16
CPCA61K31/7048
Inventor 甄随民
Owner 甄随民
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap